Experts
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Pharmaxis.
RELATED STOCKHEAD STORIES
News
Closing Bell: Today’s biggest small cap movers on the ASX
News
ASX Small Cap Lunch Wrap: Have markets stabilised after that ‘quick and severe’ correction?
Health & Biotech
Pharmaxis dealt another blow as partner backs out of second drug development
News
10 at 10: These ASX stocks are leading the rally this morning
Experts
Scopo’s Health Powerplays: Show me the (grant) money
News
Trading Places: Cybersecurity stocks are in hot demand by fund managers
Health & Biotech
Check up: A good fortnight to be a small cap health investor
Experts
Scopo’s health powerplays: quick vaccine hits and cheap buys
Health & Biotech
Pharmaxis forges ahead with phase 2 cancer drug trial in spite of COVID-19
Health & Biotech
Dr Boreham’s Crucible: Why CSL is the poster child for most junior drug developers
News
Weekly ASX small cap wrap: Who got a bit too silly in the silly season this week?
News
Lunchtime ASX small cap wrap: Who’s taking an early break today?
Health & Biotech
Health: Pharmaxis partner quits NASH drug development, shares halve
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Health: Is this the big news from Germany Pharmaxis was waiting for?
Experts
On the Radar: 5 small caps that brokers pick for growth in the months ahead
Health & Biotech
